Basel, July 1, 2019 – Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease[1].
Marie-France Tschudin, President, Novartis Pharmaceuticals, said: “This deal delivers on our ongoing commitment to reimagine medicine for patients suffering from a variety of eye diseases, while also laying critical groundwork for future, potential front-of-the-eye pipeline products we have in development.”
Date: July 08, 2019
Source: Novartis
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.